Redpin Therapeutics has appointed David Bleakman to serve as chief scientific officer of the New York biotech. Before joining Redpin, Bleakman spent 25 years at Eli Lilly (NYSE: [[ticker:LLY]]), most recently as vice president, chief scientific officer, and neuroscience site leader in New York. Redpin, a resident company at JLABS @ NYC, is developing drugs that target neuronal cell activity in the brain to treat neurological and psychiatric disorders.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
